Statement of Deviation & variation for the Quarter and Year ended March 31, 2026.
Newspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31, 2026.
Audited Financial Results for the Quarter and Year ended March 31 , 2026
Audited Financial Results for the Quarter and Year ended March 31, 2026
Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2026.
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyVenmax Drugs and Pharmaceuticals Ltd 2CIN NO.L24230TG1988PLC009102 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Priyanka Agarwal Designation: Company Secretary and Compliance Officer EmailId: venmaxdrugs@gmail.com Name of the Chief Financial Officer: Kummarikuntla Saibaba Designation: Chief Financial Officer EmailId: venmaxdrugs@gmail.com Date: 14/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Submission of Annual Secretarial Compliance Report for the year ended March 31, 2026.
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.
Disclosure under Regulation 31 (4) of SEBI (SAST) Regulations, 2011
The Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director, Non Executive and Non Independent Director and Mr. Revoor Ramachandra as an Additional director, Non Executive Independent Director of the Company.